Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 7, Number 1—February 2001

Synopsis

Quinolone and Macrolide Resistance in Campylobacter jejuni and C. coli: Resistance Mechanisms and Trends in Human Isolates

Jørgen Engberg*Comments to Author , Frank M. Aarestrup†, Diane E. Taylor‡, Peter Gerner-Smidt*, and Irving Nachamkin§
Author affiliations: *Statens Serum Institut, Copenhagen, Denmark; †Frank Aarestrup, Danish Veterinary Laboratory, Copenhagen, Denmark; ‡Diane E. Taylor, University of Alberta, Edmonton, Alberta, Canada; §Irving Nachamkin, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Main Article

Table 2

Erythromycin and azithromycin resistance rates (%) in Campylobacter in humans, worldwide, since 1989

Country C. jejuni C. coli C. jejuni and Ref.
C. coli
Austria 0.7 5.5 <1-1.4 (58 & pers. comm.a)
Canada 0-3.3 - - (59,60)
Denmark 0 14.0 0-4 (24,61,62)
Finland - - <1-3 (43,63, & pers. comm.b)
France 1.1 12.2 3.5 (64)
Hungary - - 0 (65)
Italy 1.2-6 16-68.4 7.8-11.6 (66-69)
Japan 0.8 - - (66)
New Zealand - - 1.5 (70)
Singapore - - 51 (71)
Spain 0-11.0 0-35.0 3.2-7.3 (17,27,56,57,72)
Sweden 6.4c 11.1c 7.3c (44)
Taiwan 10.0 50.0 18.3 (31)
Thailand - - 0-31.0 (73,74)
United Kingdom 1 13 1.8 (75)
United States 0-7.8 - - (10,76-78 & unpub. datad)

aG Feierl, 2000, pers. comm.
bH Rautelin, 1999, pers. comm.
c90% of isolates were acquired abroad.
dI Nachamkin, 2000, unpub. data.

Main Article

TOP